Related references
Note: Only part of the references are listed.Thermal immuno-nanomedicine in cancer
Zhe Yang et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2023)
First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
Lijuan Li et al.
BMC CANCER (2023)
Immune checkpoint inhibitor combinations-current and emerging strategies
Robert J. J. Walsh et al.
BRITISH JOURNAL OF CANCER (2023)
Dostarlimab, an anti‐programmed death‐1 monoclonal antibody, does not cause QT prolongation in patients with solid tumours: A concentration‐QT analysis
Mita Kuchimanchi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)
Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations
Francesco Cortiula et al.
EUROPEAN JOURNAL OF CANCER (2023)
Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma
Haoran Li et al.
ONCOLOGIST (2023)
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
Ainhoa Madariaga et al.
NATURE COMMUNICATIONS (2023)
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study
Alexander Lesokhin et al.
CANCER MEDICINE (2023)
Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma-A multicenter real-world experience in Israel
Itamar Averbuch et al.
CANCER MEDICINE (2023)
Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study
Kang Wang et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2023)
Current Status in Rechallenge of Immunotherapy
Han Hu et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2023)
Gastrointestinal: Pembrolizumab-induced gastric ulcer occurring as an immune-related adverse event
K. Terasaki et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2022)
COVID-19 mRNA vaccines: Platforms and current developments
Gabor Tamas Szabo et al.
MOLECULAR THERAPY (2022)
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy
Tommaso Morelli et al.
THORAX (2022)
Clinical Evaluation of Avelumab in the Treatment of Advanced Urothelial Carcinoma: Focus on Patient Selection and Outcomes
Jennifer E. Ten Eyck et al.
CANCER MANAGEMENT AND RESEARCH (2022)
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study
Ana Oaknin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Immune Checkpoint Blockade and Skin Toxicity Pathogenesis
Barbara Ma et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2022)
Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis
Kewei Liu et al.
FRONTIERS IN IMMUNOLOGY (2022)
Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative?
Yadira Palacios et al.
PHARMACEUTICALS (2022)
Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: A case report and literature review of aseptic meningitis as an immune-related adverse event
Genki Inui et al.
MOLECULAR AND CLINICAL ONCOLOGY (2022)
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer
Andrea Cercek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
The Pathogenesis and Diagnosis of Pneumocystis jiroveci Pneumonia
Anna Apostolopoulou et al.
JOURNAL OF FUNGI (2022)
An Usual Presentation of Pneumocystis jirovecii Pneumonia in a Woman Treated With Immune Checkpoint Inhibitor
Stephanie Si et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2021)
Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review
Aasir M. Suliman et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group
Vasiliki Nikolaou et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Julianne D. Twomey et al.
AAPS JOURNAL (2021)
Immune checkpoint inhibition in syngeneic mouse cancer models by a silicasome nanocarrier delivering a GSK3 inhibitor
Sean D. Allen et al.
BIOMATERIALS (2021)
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Sara Y. Tartof et al.
LANCET (2021)
A novel mouse model for checkpoint inhibitor-induced adverse events
Kieran Adam et al.
PLOS ONE (2021)
Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series
Kei Sonehara et al.
CASE REPORTS IN ONCOLOGY (2021)
LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
Christian Sordo-Bahamonde et al.
CANCERS (2021)
Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor
Marie Robert et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study
Seongman Bae et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Therapeutic Effects of Pembrolizumab Combined with Paclitaxel and Cisplatin Chemotherapy on Advanced Non-Squamous Non-Small Cell Lung Cancer and Influencing Factors
Gang Wu
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases
Valentine Inthasot et al.
ACTA CLINICA BELGICA (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Necrotizing soft tissue invasive aspergillosis in a cancer patient treated with immunosupressants due to checkpoint inhibitor-induced hepatitis
Alexandre E. Malek et al.
JOURNAL OF INFECTION (2020)
PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients
Anupam Kotwal et al.
THYROID (2020)
Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study
Taisuke Matsuya et al.
JOURNAL OF DERMATOLOGY (2020)
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
L. Paz-Ares et al.
ANNALS OF ONCOLOGY (2020)
S2686 A Rare Case of Atezolizumab-Induced Hepatotoxicity
Arjun Khadilkar et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer
Wendan Yu et al.
CELL DEATH & DISEASE (2020)
Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab
Ganessan Kichenadasse et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab
Hazim Bukamur et al.
SOUTHERN MEDICAL JOURNAL (2020)
Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
Kageaki Taima et al.
RESPIROLOGY CASE REPORTS (2020)
Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review
Atsuto Mouri et al.
IN VIVO (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Fiamma Berner et al.
JAMA ONCOLOGY (2019)
Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases
Michael Schwarz et al.
CLINICAL LUNG CANCER (2019)
Tuberculosis following PD-1 blockade for cancer immunotherapy
Daniel L. Barber et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer
Jia-Xin Li et al.
INTEGRATIVE CANCER THERAPIES (2019)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Pembrolizumab-induced acute thrombosis: A case report
Kei Kunimasa et al.
MEDICINE (2018)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
M. R. Migden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Expression of PD-1 and Tim-3 markers of T-cell exhaustion is associated with CD4 dynamics during the course of untreated and treated HIV infection
Norma Rallon et al.
PLOS ONE (2018)
Avelumab: A Review in Metastatic Merkel Cell Carcinoma
Matt Shirley
TARGETED ONCOLOGY (2018)
Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection
Fang Li et al.
CANCER MANAGEMENT AND RESEARCH (2018)
A Case of Toxic Hepatic Event Occurring in Combination Treatment with Nivolumab and Anti-Tuberculosis in Advanced Lung Cancer
T. H. Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Dermatologic Reactions to Immune Checkpoint Inhibitors Skin Toxicities and Immunotherapy
Vincent Sibaud
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
Anti-PD1-induced psoriasis: a study of 21 patients
J. Bonigen et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Severe acute interstitial lung disease after nivolumab in three non-small cell lung cancer patients with imaging findings of airway obstruction adjacent to lung tumors
Kenji Nakahama et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2017)
Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer
Terufumi Kato et al.
LUNG CANCER (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Nivolumab-induced asthma in a patient with non-small-cell lung cancer
K. Maeno et al.
ANNALS OF ONCOLOGY (2017)
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
V. R. Belum et al.
EUROPEAN JOURNAL OF CANCER (2016)
The phosphoproteome of human Jurkat T cell clones upon costimulation with anti-CD3/anti-CD28 antibodies
Tien Dung Nguyen et al.
JOURNAL OF PROTEOMICS (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Asma Beldi-Ferchiou et al.
ONCOTARGET (2016)
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
Camille Hua et al.
JAMA DERMATOLOGY (2016)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
Nivolumab: targeting PD-1 to bolster antitumor immunity
Julie R. Brahmer et al.
FUTURE ONCOLOGY (2015)
Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy
Mizuki Nishino et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Yu-Hwa Huang et al.
NATURE (2015)
Ipilimumab in patients with cancer and the management of dermatologic adverse events
Mario E. Lacouture et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Tim-3 Expression in Cervical Cancer Promotes Tumor Metastasis
Yang Cao et al.
PLOS ONE (2013)
Cis Association of Galectin-9 with Tim-3 Differentially Regulates IL-12/IL-23 Expressions in Monocytes via TLR Signaling
Cheng J. Ma et al.
PLOS ONE (2013)
ITIM-dependent negative signaling pathways for the control of cell-mediated xenogeneic immune responses
Maria-Luisa del Rio et al.
XENOTRANSPLANTATION (2013)
TIM-3 expression in human osteosarcoma: Correlation with the expression of epithelial-mesenchymal transition-specific biomarkers
Yongjun Shang et al.
ONCOLOGY LETTERS (2013)
Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
Ahmad Tarhini
SCIENTIFICA (2013)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer
John Dulos et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion
Manu Rangachari et al.
NATURE MEDICINE (2012)
CD4 T Cells Promote Rather than Control Tuberculosis in the Absence of PD-1-Mediated Inhibition
Daniel L. Barber et al.
JOURNAL OF IMMUNOLOGY (2011)
Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways
Judong Lee et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
A TNF-Regulated Recombinatorial Macrophage Immune Receptor Implicated in Granuloma Formation in Tuberculosis
Alexander W. Beham et al.
PLOS PATHOGENS (2011)
Airborne Aspergillus fumigatus conidia: a risk factor for aspergillosis
Céline M. O’Gorman
Fungal Biology Reviews (2011)
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
S. J. O'Day et al.
ANNALS OF ONCOLOGY (2010)
Efficiency of T-cell costimulation by CD80 and CD86 cross-linking correlates with calcium entry
Markus Thiel et al.
IMMUNOLOGY (2010)
PD-1 deficiency results in the development of fatal myocarditis in MRL mice
Jian Wang et al.
INTERNATIONAL IMMUNOLOGY (2010)
PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions
O. Akbari et al.
MUCOSAL IMMUNOLOGY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis
Eszter Lazar-Molnar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Structural Biology of the T-cell Receptor: Insights into Receptor Assembly, Ligand Recognition, and Initiation of Signaling
Kai W. Wucherpfennig et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Negative Immune Regulator Tim-3 Is Overexpressed on T Cells in Hepatitis C Virus Infection and Its Blockade Rescues Dysfunctional CD4+ and CD8+ T Cells
Lucy Golden-Mason et al.
JOURNAL OF VIROLOGY (2009)
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection
R. Brad Jones et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
Stephanie G. Downey et al.
CLINICAL CANCER RESEARCH (2007)
Molecular signature of CD8+ T cell exhaustion during chronic viral infection
E. John Wherry et al.
IMMUNITY (2007)
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade
AV Maker et al.
JOURNAL OF IMMUNOLOGY (2005)
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
E Contardi et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
T-cell regulation by CD28 and CTLA-4
ML Alegre et al.
NATURE REVIEWS IMMUNOLOGY (2001)